Oncology | CHOP Research Institute
 

Oncology

Cornerstone Blog

How Does Chemotherapy Affect the Neuroblastoma Tumor-Immune Cell Microenvironment?

Published on
May 7, 2025
CHOP Researchers Create Cell Atlas of High-Risk Neuroblastoma
Using advanced omics and computational techniques, the researchers found that both cancer and immune cells changed after treatment.

PEEL-224 in Solid Tumors

This study enrolls patients with refractory, progressive, or relapsed solid tumors.

Massage Impact on Sleep in Pediatric Oncology

This study enrolls patients with cancer diagnoses who are expected to be hospitalized (inpatient) for at least 21 days.

Cornerstone Blog

‘Breakthrough’ Phase 3 Study Changes Standard of Care for Childhood B-cell Leukemia

Published on
Jan 6, 2025
Phase 3 Study Changes Standard of Care for Childhood B-cell Leukemia
The CHOP-led trial showed that blinatumomab plus chemotherapy drastically improved survival rates for patients with B-ALL.
Cornerstone Blog

Alex’s Lemonade Stand Powers 20 Years of Pediatric Cancer Research at CHOP

Published on
Dec 19, 2024
Alex’s Lemonade Stand and CHOP: A 20-year Collaboration
As the pediatric cancer charity celebrates its 20th anniversary, Cornerstone is highlighting the groundbreaking research at CHOP fueled by two decades of collaboration.

PTX-022 in the Treatment of Microcystic Lymphatic Malformations

PTX-022 in the Treatment of Microcystic Lymphatic Malformations

The purpose of this study is to see if a new investigational topical (applied to the skin) formulation of sirolimus, PTX-022 (the study drug), is safe and effective in treating participants with microcystic Lymphatic Malformations.

Cornerstone Blog

Hyundai Hope On Wheels Supports Neuroblastoma Research at CHOP

Published on
Oct 30, 2024
Hyundai Hope On Wheels Supports Neuroblastoma Research
Adam Wolpaw, MD, PhD, and Timothy Spear, MD, PhD, have been awarded grants from Hyundai Hope On Wheels to improve CAR T-cell therapy.

INBRX-109 in Ewing Sarcoma and Gastrointestinal Stromal Tumor (GIST)

This study involves taking a study drug called INBRX-109.

Ruxolitinib After Hematopoietic Stem Cell Transplant (HSCT)

This study is enrolling people who have developed lung problems (called Bronchiolitis Obliterans or BO) after hematopoietic stem cell transplant (HSCT).

Cornerstone Blog

What Are the Genomic Drivers of Childhood T-ALL?

Published on
Sep 30, 2024
What Are the Genomic Drivers of Childhood T-ALL?
CHOP researchers uncovered 15 subtypes of T-cell acute lymphoblastic leukemia, which will help to predict outcomes and guide treatment.